NanoViricides, Inc. (NNVC) |
|
1.435 0.035 (2.5%)
|
09-27 10:36 |
|
Open: |
1.45 |
Pre. Close: |
1.4 |
|
High:
|
1.45 |
Low:
|
1.41 |
|
Volume:
|
7,932 |
Market Cap:
|
17(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:18:17 AM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 1.79  One year: 1.99 |
| Support: |
Support1: 1.25 Support2: 1.04 |
| Resistance: |
Resistance1: 1.53 Resistance2: 1.71 |
| Pivot: |
1.31 |
| Moving Average: |
MA(5): 1.34 MA(20): 1.34
MA(100): 1.31 MA(250): 1.38 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 61.1 %D(3): 34.6 |
| RSI: |
RSI(14): 58.9 |
| 52-week: |
High: 2 Low: 1.03 |
| Average Vol(K): |
3-Month: 99 (K) 10-Days: 16 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NNVC ] has closed Bollinger Bands are 43.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.41 - 1.41 |
1.41 - 1.42 |
|
Low:
|
1.35 - 1.35 |
1.35 - 1.36 |
|
Close:
|
1.39 - 1.4 |
1.4 - 1.41 |
|
Company Description |
|
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut. |
Headline News |
Wed, 27 Sep 2023
Multi-Billion Dollar Treatment Market For Lung Infection That Causes ... - InvestorsObserver
Tue, 22 Aug 2023
Healthcare Stocks Moving Up and Down Tuesday: FULC, CNSP, NNVC, NVAX, GERN, CRVO, ALVR, EBS - InvestorsObserver
Mon, 21 Aug 2023
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s ... - BioSpace
Tue, 18 Jul 2023
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COV - Benzinga
Thu, 13 Jul 2023
NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst - Yahoo Finance
Tue, 11 Jul 2023
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket - Better Therapeut - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
